TAK 029

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526404

CAS#: 176655-58-6

Description: TAK 029 is a local glycoprotein IIb/IIIa receptor inhibitor.


Price and Availability

Size
Price

Size
Price

Size
Price

TAK 029 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 526404
Name: TAK 029
CAS#: 176655-58-6
Chemical Formula: C18H21N5O7
Exact Mass: 419.1441
Molecular Weight: 419.394
Elemental Analysis: C, 51.55; H, 5.05; N, 16.70; O, 26.70


Synonym: TAK 029, TAK029, TAK-029

IUPAC/Chemical Name: 4-(4-Amidinobenzoylglycyl)-3-methoxycarbonyl-2-oxopiperazine-1-acetic acid

InChi Key: CBGVKPBTAJZSMX-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H21N5O7/c1-30-18(29)14-17(28)22(9-13(25)26)6-7-23(14)12(24)8-21-16(27)11-4-2-10(3-5-11)15(19)20/h2-5,14H,6-9H2,1H3,(H3,19,20)(H,21,27)(H,25,26)

SMILES Code: O=C(O)CN1C(C(C(OC)=O)N(C(CNC(C2=CC=C(C(N)=N)C=C2)=O)=O)CC1)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Linneweber J, Dohmen PM, Kertzscher U, Affeld K, Konertz W. Local glycoprotein IIb/IIIa receptor inhibitor delivery from the pump surface attenuates platelet adhesion in continuous flow ventricular assist devices. Artif Organs. 2008 Oct;32(10):792-9. doi: 10.1111/j.1525-1594.2008.00632.x. PubMed PMID: 18959668.

2: Yamamoto J, Yamashita T, Ikarugi H, Taka T, Hashimoto M, Ishii H, Watanabe S, Kovacs IB. Görög Thrombosis Test: a global in-vitro test of platelet function and thrombolysis. Blood Coagul Fibrinolysis. 2003 Jan;14(1):31-9. PubMed PMID: 12544726.

3: Tomita Y, Tanahashi N, Tomita M, Itoh Y, Yokoyama M, Takeda H, Schiszler I, Fukuuchi Y. Role of platelet glycoprotein IIb/IIIa in ADP-activated platelet adhesion to aortic endothelial cells in vitro: observation with video-enhanced contrast microscopy. Clin Hemorheol Microcirc. 2001;24(1):1-9. PubMed PMID: 11345228.

4: Kitamura S, Fukushi H, Miyawaki T, Kawamura M, Terashita Z, Sugihara H, Naka T. Novel non-peptide GPIIb/IIIa antagonists: synthesis and biological activities of 2-[4-[2-(4-amidinobenzoylamino)-2-(substituted)acetyl]-3-(2-methoxy-2-oxoethyl)-2 -oxopiperazinyl] acetic acids. Chem Pharm Bull (Tokyo). 2001 Mar;49(3):258-67. PubMed PMID: 11253914.

5: Tanahashi N, Fukuuchi Y, Tomita M, Tomita Y, Inoue K, Satoh H, Abe T. Adhesion of adenosine diphosphate-activated platelets to human brain microvascular endothelial cells under flow in vitro is mediated via GPIIb/IIIa. Neurosci Lett. 2001 Mar 23;301(1):33-6. PubMed PMID: 11239710.

6: Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Coller BS. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation. 1999 Feb 9;99(5):620-5. PubMed PMID: 9950658.

7: Kawahito K, Fujimura A, Kobayashi E, Misawa Y, Fuse K. Platelet protective effect of TAK-029, a novel glycoprotein IIb/IIIa antagonist: an in vitro study. Artif Organs. 1998 Apr;22(4):348-52. PubMed PMID: 9555968.

8: Takada S, Ogawa Y. [Design and development of controlled release of drugs from injectable microcapsules]. Nihon Rinsho. 1998 Mar;56(3):675-9. Review. Japanese. PubMed PMID: 9549355.

9: Sugihara H, Fukushi H, Miyawaki T, Imai Y, Terashita Z, Kawamura M, Fujisawa Y, Kita S. Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide. J Med Chem. 1998 Feb 12;41(4):489-502. PubMed PMID: 9484499.

10: Takada S, Kurokawa T, Miyazaki K, Iwasa S, Ogawa Y. Utilization of an amorphous form of a water-soluble GPIIb/IIIa antagonist for controlled release from biodegradable microspheres. Pharm Res. 1997 Sep;14(9):1146-50. PubMed PMID: 9327440.

11: Kawamura M, Tsuji N, Moriya N, Terashita Z. Effects of TAK-029, a novel GPIIb/IIIa antagonist, on arterial thrombosis in guinea pigs, dogs and monkeys. Thromb Res. 1997 May 15;86(4):275-85. PubMed PMID: 9187016.

12: Kawamura M, Imura Y, Moriya N, Kita S, Fukushi H, Sugihara H, Nishikawa K, Terashita Z. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban. J Pharmacol Exp Ther. 1996 Apr;277(1):502-10. PubMed PMID: 8613960.